PSA-screening cuts deaths from prostate cancer by some 30%. This is shown by research based on data on 20,000 men monitored for more than two decades. The men's initially measured PSA level proved highly significant as a predictor of future cancer risk.
"This research is important because it shows the long-term effects of an organized screening program in Sweden," says Maria Franlund, MD, PhD in Urology at Sahlgrenska Academy, University of Gothenburg, Sweden, and Head of Department at Sahlgrenska University Hospital.
Franlund's thesis on prostate cancer screening comes after the latest (2018) recommendation from the Swedish National Board of Health and Welfare: that health services should not offer screening with PSA testing alone. The reason is that the Board regards the drawbacks of PSA screening -- overdiagnosis and overtreatment -- as outweighing its benefits.
The main purpose of this research has been to enhance understanding of the implications of screening, and of the possible design of a future screening program for prostate cancer.
Franlund's thesis work originates from a large, population-based study that started in Gothenburg in 1995. The study is unique in many ways, and currently has the longest follow-up period of all screening studies on prostate cancer worldwide.
Initially, the Randomized Population-Based Prostate ...